Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
37 employees
Pipeline Therapeutics: Biopharmaceutical firm developing regenerative therapies for neurological diseases.
HQ
Founded
2017
Pipeline Therapeutics, founded with a mission to develop regenerative therapies, aims to promote the functional recovery of neurological diseases. The company focuses on creating precision small molecules that leverage the natural repair processes in nervous system cell types. Their primary market includes patients suffering from conditions such as multiple sclerosis, offering treatments designed to repair damage to the nervous system and improve clinical outcomes.
Notable affiliated individuals and investors include experts in neuroscience, inflammation, and immunology, though specific names are not provided. Pipeline Therapeutics has achieved significant milestones in advancing their therapeutic candidates through preclinical and early clinical development stages. Their innovative approach has the potential to make a substantial impact on the treatment landscape for neurological diseases, contributing to improved patient quality of life and advancing the field of regenerative medicine.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Regenerative Therapies
Technology
Biotech
Tags
Biotech
Model Types
Biotech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Pipeline Therapeutics founded?
Pipeline Therapeutics was founded in 2017.
Where is Pipeline Therapeutics's headquarters located?
Pipeline Therapeutics's headquarters is located in San Diego, CA, US.
When was Pipeline Therapeutics's last funding round?
Pipeline Therapeutics's most recent funding round was for $80M (USD) in February 2021.
How many employees does Pipeline Therapeutics have?
Pipeline Therapeutics has 37 employees as of Feb 4, 2024.
How much has Pipeline Therapeutics raised to-date?
As of July 05, 2023, Pipeline Therapeutics has raised a total of $112M (USD) since Feb 11, 2021.
Add Comparison
Total Raised to Date
$112M
USD
Last Update Feb 11, 2021
Last Deal Details
$80M
USD
Feb 11, 2021
Series C
Current Employees
37
Last updated: Feb 4, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts